How often will I receive my bispecific therapy? 

The frequency of how often you receive your therapy will be determined by both the specific therapy you are given and how long you have taken said therapy. 

  Elranatamab (BCMA-directed) is given as an injection once a week, but after twenty-four doses, the therapy can be given every two weeks instead of weekly. 

For teclistamab (BCMA-directed), after the initial step-up dosing phase, the treatment is continued once weekly. If patients achieve a complete response for six months or more, they can be moved to a lower dose administered every other week. 

With talquetamab (GPRC5D-directed), the physician and patient can choose whether a weekly or biweekly subcutaneous injection after the initial step-up dosing phase is appropriate. 

This section will continue to be updated as more bispecific antibody therapies are approved.